AI is accelerating everything from the speed with which individuals can create grocery lists to the speed with which drug manufacturers’ drug discovery timelines are rolled out. However, many in the healthcare industry cling to old R&D strategies that are no longer viable in the era of automation and machine learning. This change is structural and not gradual. Those who keep going slow and steady will not win this race.
As AI and personalized medicine reshape the healthcare landscape, pharmaceutical and biotech companies can no longer afford a cautious, incremental R&D strategy. Only by adopting a venture-building mindset that prioritizes rapid experimentation and structural innovation can you remain competitive in an era where speed is valued over certainty.
When “watching and learning” becomes a duty
Many medical institutions have fallen into the “wait-and-see” trap. While this tactic may seem strategic, it’s actually just slow. By avoiding experimentation, organizations are already falling behind those that choose to act. There are costs to doing nothing, including talent, intellectual property, and market position. The best time to experiment was 10 years ago. The second best time is now.
Forces are moving rapidly to rewrite the rules of medical innovation. AI and machine learning are dramatically shortening drug discovery timelines and changing the competitive moat. Personalized medicine is fragmenting mass market models and requires new operating structures. Continuous and rapid regulatory evolution is causing government agencies to move faster than expected and leaving most in-house teams scrambling to keep up. The consequences of these forces require structural rather than tactical responses.
Venture building in a healthcare context
Venture Building is a structured engine for creating startups that solve real-world problems. Venture incubation programs not only solve pressing industry challenges, but also provide something equally valuable. In other words, dramatically accelerate organizational learning. This is because startups have fewer bureaucratic constraints and are structurally motivated to: create than that protectcan move from hypothesis to experimentation to insight much faster than established organizations. The speed will further accelerate. Each cycle of experimentation builds the knowledge base for the next cycle, creating a continuous cycle of innovation that cannot be replicated through traditional structures.
When executed intentionally, venture building can be a systematic path to generating a portfolio of companies that address real market gaps and create meaningful value not only for end users, but also for the parent organization, its partners, and the broader ecosystem in which it operates.
In practice, this often means working with external specialist venture builders to surface unmet needs and identify strategic white spaces where new companies can make a real impact. The goal is to find the intersection of market imperatives and organizational capabilities and build toward it through experimentation with business models that are too time-consuming, too risky, or too structurally difficult to pursue internally.
Speed over certainty
Start-ups founded by venture capitalists can value speed over certainty. Historically, the established process in the healthcare industry was to wait for certainty before committing resources because failure could cost hundreds of millions of dollars. Startups, on the other hand, have the agility and ability to run more experiments faster and extract learnings from each one, regardless of the outcome.
This is what speed really means over certainty. Startups aren’t abandoning scientific standards or rushing to validate their products. They recognize that the ability to quickly generate and test hypotheses has become a core competency in a landscape reshaped by AI and personalized medicine.
Venture-founded startups are structurally optimized for exactly this. Parallel experimentation across business models, therapeutic approaches, and delivery mechanisms can occur simultaneously, unencumbered by traditional processes and conservation instincts that slow down large organizations. The portfolio of ventures moves in parallel, increasing the organization’s surface area for discovery.
The forces reshaping health care are not on a timeline that allows for systemic hesitation. Venture building is not a silver bullet, and framing it in that way is harmful. It requires real structural commitment, real leadership courage, and a willingness to look different from the rest of the industry long enough for it to start having an effect. None of this is easy within an organization built in a different era.
But the alternative of continuing to treat cautious incrementalism as a viable strategy while the competitive landscape is reshaped runs the risk of trivializing the discomforts of change. An experiment you don’t run today doesn’t just mean you missed a learning opportunity. In a market where speed is important, that’s an advantage competitors build on.
About Elliot Parker
Elliott Parker is the CEO of Alloy Partners, a venture builder that works with companies and entrepreneurs to create profitable startups. He has launched dozens of startups at pioneering venture studio High Alpha and helped Fortune 100 companies design and execute growth strategies at Clayton Christensen’s company Innosight. Elliott is passionate about helping large organizations move quickly and think boldly, and wrote The Fantasy of Innovation to inspire change through bold experimentation. thank you
